Feb 19 / 2020
Latest News / Editorial/ Health

Valens to export white label products to Australia

Shipments will consist of three SKUs of tinctures, totaling over 3,000 units and are expected to be shipped in Q2

Valens GroWorks Corp, a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products, is pleased to announce its first international shipments of white label products to  customers in Australia. Based on the purchase orders received, the initial shipments will consist of three SKUs of tinctures, totaling over 3,000 units, and are expected to be shipped in Q2, pending receipt of necessary import and export permits.

Tyler Robson, CEO of The Valens Company.

“These first international shipments of white label cannabis products, mark a major milestone for Valens,” said Tyler Robson, CEO of The Valens Company. “We believe Australia’s strong underlying demand for cannabis products, together with the continued adoption of medical cannabis laws and relaxation of CBD laws, will drive sustained growth in the Australian market. Valens intends to continue to expand its footprint in Australia as well as other key international markets as global legal markets opens up.”

Australia’s medical cannabis program:

In 2019, there were over 25,000 prescription approvals for medicinal cannabis products in Australia, which is nearly a nine-fold increase over the number of prescription approvals in 2018. The increase in prescription approvals is in part due to the establishment of the Special Access Scheme (SAS) online system which served to streamline the application process pertaining to the prescription of, and subsequent access to, medicinal cannabis products in Australia.

In January 2020, the Australian Department of Health made a public submission to a Senate committee which indicated that the Australian Therapeutics Goods Administration is currently undertaking a review of CBD at lower doses. The submission further indicated that based on the outcome of these studies it is possible that relaxation of the scheduling status of low dose cannabidiol (CBD) to over-the-counter status could be considered during 2020.

Valens views the submission as a potential catalyst for the further relaxation of legal cannabis in Australia and with these shipments expands its relationships within the Australian market to position itself as a leader.

About Medical Cannabiz World:

In November 2019, Medical Cannabiz World opened its doors to the medicinal cannabis industry, supported by the Maltese government’s commitment to legislation for this high growth sector.  Medical Cannabiz World summit 2020 will focus on the Malta medical cannabis industry as well as global opportunities in the sector, attracting investors, medical researchers, policy makers and entrepreneurs looking to forge exciting new opportunities.

Share this entry: gplus-button facebook-button linkedin-button twitter-button
or go back to NEWS page